LGND.US Ligand Pharmaceuticals Incorporated

Healthcare Biotechnology USA Stocks
308.79 USD
Close of Nov 15, 2026
175.89 326.63
Market cap
USD 6.18B
P/E
124.0x
P/B
6.43x
ROE
0.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LGND.US undervalued?

Graham number

The Graham number of Ligand Pharmaceuticals Incorporated cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ligand Pharmaceuticals Incorporated fundamental analysis

No fundamental analysis for Ligand Pharmaceuticals Incorporated yet.

Ligand Pharmaceuticals Incorporated stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma…

Full company profile